Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Henry Chambers, III, MD

    SchoolUCSF School of Medicine
    Address1001 Potrero Ave, SFGH 30
    San Francisco CA 94110
    vCardDownload vCard
      Other Positions
      TitleChief, Division of Infectious Diseases, SFGH

      TitleDirector, Clinical Research Services, CTSI

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine
      Vanderbilt UniversityM.D.School of Medicine
      Centre College Kentucky B.A.

      Collapse Overview 
      Collapse Overview
      Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

      Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1985 where he currently is Professor of Medicine, Chief of Infectious Diseases at San Francisco General Hospital, and Director of the UCSF Infectious Diseases Fellowship Training Program. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections, and Chair of the Clinical Research and Field Studies Study Section for NIAID.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse NIH Awarded Grants
      Collapse Clinical Trials
      Collapse Global Health
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Calderwood SB, Murray BE, Chambers HF. The 21st Century Cures Act. N Engl J Med. 2015 Oct 22; 373(17):1679.
        View in: PubMed
      2. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Sep 1; 61(5):800-6.
        View in: PubMed
      3. Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, Daum RS. USA300 and USA500 Clonal Lineages of Staphylococcus aureus Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the cap5 Locus. MBio. 2015; 6(2).
        View in: PubMed
      4. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative Efficacies of Tedizolid Phosphate, Vancomycin, and Daptomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrob Agents Chemother. 2015 Jun; 59(6):3252-6.
        View in: PubMed
      5. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015 Mar 19; 372(12):1093-103.
        View in: PubMed
      6. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015 May; 59(5):2960-3.
        View in: PubMed
      7. Chambers HF. Probability of Eradication Using Vancomycin Alone or in Combination for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2014 Dec; 58(12):7617.
        View in: PubMed
      8. Archibald-Seiffer N, Weiss J, Shea K, Edmonds E, Hennrikus W, Polousky J, Heyworth B, Chambers H, McIntosh A, Murnaghan L, Busch M. Cases and current concepts in pediatric sports medicine. J Pediatr Orthop. 2014 Oct-Nov; 34 Suppl 1:S49-56.
        View in: PubMed
      9. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15; 59(2):e10-52.
        View in: PubMed
      10. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15; 59(2):147-59.
        View in: PubMed
      11. Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med. 2014 Jun 5; 370(23):2238-9.
        View in: PubMed
      12. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. Clin Infect Dis. 2014 Sep 15; 59(6):798-807.
        View in: PubMed PMC4200044
      13. Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun; 58(11):1571-6.
        View in: PubMed PMC4017892
      14. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. J Infect Dis. 2014 May 15; 209(10):1542-50.
        View in: PubMed
      15. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis. 2013 Jul; 208(1):75-82.
        View in: PubMed PMC3666136
      16. Chambers HF. Cellulitis, by any other name. Clin Infect Dis. 2013 Jun; 56(12):1763-4.
        View in: PubMed
      17. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2012 Sep; 55(6):781-8.
        View in: PubMed PMC3657511
      18. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012 Sep; 55(5):615-20.
        View in: PubMed PMC3491851
      19. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 2012 Feb; 8(2):e1002505.
        View in: PubMed PMC3271070
      20. Graber CJ, Shane AL, Weintrub P, Chambers HF. Clonality of Staphylococcus aureus colonization over time in attendees of a camp for children with chronic dermatoses. Pediatr Dermatol. 2011 Sep-Oct; 28(5):519-23.
        View in: PubMed
      21. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, Shabb DW, Diep BA, Chambers HF, Otto M, DeLeo FR. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One. 2011; 6(4):e18617.
        View in: PubMed PMC3078114
      22. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1; 52(3):285-92.
        View in: PubMed
      23. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1; 52(3):e18-55.
        View in: PubMed
      24. Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother. 2010 Nov; 54(11):4900-2.
        View in: PubMed PMC2976154
      25. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5587-92.
        View in: PubMed PMC2851770
      26. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010 May 1; 375(9725):1557-68.
        View in: PubMed PMC3511788
      27. Graves SF, Kobayashi SD, Braughton KR, Diep BA, Chambers HF, Otto M, Deleo FR. Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants. Microbes Infect. 2010 Jun; 12(6):446-56.
        View in: PubMed PMC2883622
      28. Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. J Clin Microbiol. 2010 Feb; 48(2):568-74.
        View in: PubMed PMC2815625
      29. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010 Feb; 54(2):610-3.
        View in: PubMed PMC2812130
      30. Miragaia M, de Lencastre H, Perdreau-Remington F, Chambers HF, Higashi J, Sullam PM, Lin J, Wong KI, King KA, Otto M, Sensabaugh GF, Diep BA. Genetic diversity of arginine catabolic mobile element in Staphylococcus epidermidis. PLoS One. 2009; 4(11):e7722.
        View in: PubMed PMC2768820
      31. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009 Sep; 7(9):629-41.
        View in: PubMed PMC2871281
      32. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009 Sep; 119(9):2464-74.
        View in: PubMed PMC2735934
      33. Winston L, Chambers H. Coming home with MRSA. Arch Intern Med. 2009 Aug 10; 169(15):1379-80.
        View in: PubMed
      34. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis. 2009 May 15; 48(10):1483-4.
        View in: PubMed
      35. Tattevin P, Basuino L, Chambers HF. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Res Microbiol. 2009 Apr; 160(3):187-92.
        View in: PubMed
      36. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2009 Apr 7; 106(14):5883-8.
        View in: PubMed PMC2667066
      37. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15; 48(6):713-21.
        View in: PubMed
      38. Chambers HF. Pathogenesis of staphylococcal infection: a manner of expression. J Infect Dis. 2009 Feb 1; 199(3):291-3.
        View in: PubMed
      39. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother. 2009 Apr; 53(4):1463-7.
        View in: PubMed PMC2663086
      40. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008 Oct 1; 49(2):231-3.
        View in: PubMed
      41. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One. 2008; 3(9):e3198.
        View in: PubMed PMC2527530
      42. Chambers HF, Moellering RC, Kamitsuka P. Clinical decisions. Management of skin and soft-tissue infection. N Engl J Med. 2008 Sep 4; 359(10):1063-7.
        View in: PubMed
      43. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008 Jul 28; 168(14):1585-91.
        View in: PubMed
      44. Xiong YQ, Bensing BA, Bayer AS, Chambers HF, Sullam PM. Role of the serine-rich surface glycoprotein GspB of Streptococcus gordonii in the pathogenesis of infective endocarditis. Microb Pathog. 2008 Oct; 45(4):297-301.
        View in: PubMed PMC2574613
      45. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1; 46 Suppl 5:S368-77.
        View in: PubMed
      46. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2008 Jun 1; 197(11):1523-30.
        View in: PubMed
      47. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008 Jun 1; 46(11):1637-46.
        View in: PubMed
      48. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jun; 52(6):2089-96.
        View in: PubMed PMC2415812
      49. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. JAMA. 2008 Feb 6; 299(5):519; author reply 519-20.
        View in: PubMed
      50. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19; 148(4):249-57.
        View in: PubMed
      51. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007 Nov; 51(11):4044-8.
        View in: PubMed PMC2151464
      52. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert Rev Anti Infect Ther. 2007 Jun; 5(3):333-5.
        View in: PubMed
      53. Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM. Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB. Mol Microbiol. 2007 May; 64(3):844-57.
        View in: PubMed
      54. Rajendran PM, Young DM, Maurer T, Chambers HF, Jacobson MA, Harris HW. Antibiotic use in the treatment of soft tissue abscesses: a survey of current practice. Surg Infect (Larchmt). 2007 Apr; 8(2):237-8.
        View in: PubMed
      55. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis. 2007 Mar; 13(3):491-3.
        View in: PubMed PMC2725904
      56. Chambers HF. Intramuscular versus intravenous administration of benzathine penicillin. Clin Infect Dis. 2007 Jan 1; 44(1):151; author reply 151-2.
        View in: PubMed
      57. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17; 355(7):653-65.
        View in: PubMed
      58. Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology. 2006 Aug; 113(8):1455-62.
        View in: PubMed
      59. Seeley EJ, Chambers HF. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature. Clin Infect Dis. 2006 Jul 1; 43(1):e6-8.
        View in: PubMed
      60. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect. 2006 Apr; 12 Suppl 2:17-22.
        View in: PubMed
      61. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005 Nov 15; 41(10):1373-406.
        View in: PubMed
      62. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Aug; 49(8):3163-5.
        View in: PubMed PMC1196289
      63. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005 Jul; 49(7):2816-21.
        View in: PubMed PMC1168716
      64. Katayama Y, Robinson DA, Enright MC, Chambers HF. Genetic background affects stability of mecA in Staphylococcus aureus. J Clin Microbiol. 2005 May; 43(5):2380-3.
        View in: PubMed PMC1153748
      65. Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin Infect Dis. 2005 Jun 1; 40(11):1617-24.
        View in: PubMed
      66. Chambers HF. Community-associated MRSA--resistance and virulence converge. N Engl J Med. 2005 Apr 7; 352(14):1485-7.
        View in: PubMed
      67. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Infect Immun. 2005 Apr; 73(4):2273-80.
        View in: PubMed PMC1087419
      68. Chambers HF. Staphylococcal purpura fulminans: a toxin-mediated disease? Clin Infect Dis. 2005 Apr 1; 40(7):948-50.
        View in: PubMed
      69. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Mar; 49(3):884-8.
        View in: PubMed PMC549268
      70. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. Am J Infect Control. 2004 Dec; 32(8):462-9.
        View in: PubMed
      71. Winston LG, Felt SC, Huang WH, Chambers HF. Introduction of a waterless hand gel was associated with a reduced rate of ventilator-associated pneumonia in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2004 Dec; 25(12):1015-6.
        View in: PubMed
      72. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004 Sep; 139(9):947-51; discussion 951-3.
        View in: PubMed
      73. Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J Biol Chem. 2004 Nov 5; 279(45):47278-87.
        View in: PubMed
      74. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2004 Jul 1; 39(1):47-54.
        View in: PubMed PMC2567833
      75. Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin. Diagn Microbiol Infect Dis. 2004 Apr; 48(4):287-8.
        View in: PubMed
      76. Chambers HF, Winston LG. Mupirocin prophylaxis misses by a nose. Ann Intern Med. 2004 Mar 16; 140(6):484-5.
        View in: PubMed
      77. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004 Apr 1; 38(7):994-1000.
        View in: PubMed
      78. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother. 2004 Feb; 48(2):453-9.
        View in: PubMed PMC321522
      79. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003 Oct; 47(10):3040-5.
        View in: PubMed PMC201119
      80. Katayama Y, Zhang HZ, Hong D, Chambers HF. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 2003 Sep; 185(18):5465-72.
        View in: PubMed PMC193760
      81. Chambers HF. Solving staphylococcal resistance to beta-lactams. Trends Microbiol. 2003 Apr; 11(4):145-8.
        View in: PubMed
      82. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother. 2003 Apr; 47(4):1262-6.
        View in: PubMed PMC152514
      83. Tabas JA, Chambers HF. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2003 Mar 6; 348(10):954-7; author reply 954-7.
        View in: PubMed
      84. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. Semin Respir Crit Care Med. 2003 Feb; 24(1):37-48.
        View in: PubMed
      85. Katayama Y, Zhang HZ, Chambers HF. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Microb Drug Resist. 2003; 9(4):329-36.
        View in: PubMed
      86. Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital. Am J Infect Control. 2002 Nov; 30(7):400-6.
        View in: PubMed
      87. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis. 2002 Feb 15; 34(4):425-33.
        View in: PubMed
      88. Kanaya AM, Glidden DV, Chambers HF. Identifying pulmonary tuberculosis in patients with negative sputum smear results. Chest. 2001 Aug; 120(2):349-55.
        View in: PubMed
      89. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2001 Jul 3; 98(14):7958-63.
        View in: PubMed PMC35450
      90. Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. Science. 2001 Mar 9; 291(5510):1962-5.
        View in: PubMed
      91. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001 Mar-Apr; 7(2):178-82.
        View in: PubMed PMC2631711
      92. Chambers HF. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. Postgrad Med. 2001 Feb; 109(2 Suppl):43-50.
        View in: PubMed
      93. Chambers HF, Xiang Q. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob Agents Chemother. 1999 Nov; 43(11):2742-6.
        View in: PubMed PMC89553
      94. Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, Chambers HF, Täuber MG, Lee BL. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis. 1999 Sep; 180(3):896-9.
        View in: PubMed
      95. Grüneberg RN, Antunes F, Chambers HF, Garau J, Graninger W, Menichetti F, Peetermans WE, Pittet D, Shah PM, Vogelaers D. The role of glycopeptide antibiotics in the treatment of infective endocarditis. Int J Antimicrob Agents. 1999 Aug; 12(3):191-8.
        View in: PubMed
      96. Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis. 1999 Mar; 179 Suppl 2:S353-9.
        View in: PubMed
      97. Bayer AS, Bolger AF, Taubert KA, Wilson W, Steckelberg J, Karchmer AW, Levison M, Chambers HF, Dajani AS, Gewitz MH, Newburger JW, Gerber MA, Shulman ST, Pallasch TJ, Gage TW, Ferrieri P. Diagnosis and management of infective endocarditis and its complications. Circulation. 1998 Dec 22-29; 98(25):2936-48.
        View in: PubMed
      98. Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Dec; 42(12):3325-7.
        View in: PubMed PMC106048
      99. Gilbert DN, Lee BL, Dworkin RJ, Leggett JL, Chambers HF, Modin G, Täuber MG, Sande MA. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med. 1998 Sep; 105(3):182-91.
        View in: PubMed
      100. Sheppard DC, Chambers HF. Suppurative parotitis. West J Med. 1998 Aug; 169(2):116-7.
        View in: PubMed PMC1305186
      101. Perdreau-Remington F, Sande MA, Peters G, Chambers HF. The abilities of a Staphylococcus epidermidis wild-type strain and its slime-negative mutant to induce endocarditis in rabbits are comparable. Infect Immun. 1998 Jun; 66(6):2778-81.
        View in: PubMed PMC108269
      102. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis. 1998 Apr; 26(4):874-7.
        View in: PubMed
      103. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997 Oct; 10(4):781-91.
        View in: PubMed PMC172944
      104. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother. 1997 May; 41(5):1182-5.
        View in: PubMed PMC163878
      105. Sweet-Cordero EA, Chambers HF, Cicero-Sabido R, Santos-Preciado JI. Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay. Tuber Lung Dis. 1996 Dec; 77(6):496-501.
        View in: PubMed
      106. Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother. 1996 Aug; 40(8):1768-74.
        View in: PubMed PMC163415
      107. Knapp CC, Ludwig MD, Washington JA, Chambers HF. Evaluation of Vitek GPS-SA card for testing of oxacillin against borderline-susceptible staphylococci that lack mec. J Clin Microbiol. 1996 Jul; 34(7):1603-5.
        View in: PubMed PMC229078
      108. Frank U, Chambers HF. Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model. Antimicrob Agents Chemother. 1996 May; 40(5):1308-10.
        View in: PubMed PMC163317
      109. Lee BL, Täuber MG, Sadler B, Goldstein D, Chambers HF. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther. 1996 Jan; 59(1):14-21.
        View in: PubMed
      110. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother. 1995 Dec; 39(12):2620-4.
        View in: PubMed PMC163000
      111. Barton RN, Cocks RA, Doyle MO, Chambers H. Time course of the early pituitary-adrenal and metabolic responses to accidental injury. J Trauma. 1995 Nov; 39(5):888-94.
        View in: PubMed
      112. Yajko DM, Wagner C, Tevere VJ, Kocagöz T, Hadley WK, Chambers HF. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. J Clin Microbiol. 1995 Jul; 33(7):1944-7.
        View in: PubMed PMC228308
      113. Chambers HF, Kartalija M, Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis. 1995 Apr; 171(4):897-902.
        View in: PubMed
      114. Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob Agents Chemother. 1995 Feb; 39(2):462-6.
        View in: PubMed PMC162561
      115. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrob Agents Chemother. 1995 Jan; 39(1):103-6.
        View in: PubMed PMC162493
      116. Hackbarth CJ, Miick C, Chambers HF. Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Nov; 38(11):2568-71.
        View in: PubMed PMC188243
      117. Chambers HF, Sachdeva MJ, Hackbarth CJ. Kinetics of penicillin binding to penicillin-binding proteins of Staphylococcus aureus. Biochem J. 1994 Jul 1; 301 ( Pt 1):139-44.
        View in: PubMed PMC1137153
      118. Chambers HF. Transesophageal echocardiography in endocarditis. Chest. 1994 Feb; 105(2):333-4.
        View in: PubMed
      119. Sullam PM, Frank U, Yeaman MR, Täuber MG, Bayer AS, Chambers HF. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis. 1993 Oct; 168(4):910-4.
        View in: PubMed
      120. Chambers HF, Fournier MA. Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. J Antimicrob Chemother. 1993 Sep; 32(3):453-8.
        View in: PubMed
      121. Kocagöz T, Yilmaz E, Ozkara S, Kocagöz S, Hayran M, Sachedeva M, Chambers HF. Detection of Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified procedure. J Clin Microbiol. 1993 Jun; 31(6):1435-8.
        View in: PubMed PMC265557
      122. Chambers HF. Detection of methicillin-resistant staphylococci. Infect Dis Clin North Am. 1993 Jun; 7(2):425-33.
        View in: PubMed
      123. Hackbarth CJ, Chambers HF. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May; 37(5):1144-9.
        View in: PubMed PMC187918
      124. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am. 1993 Mar; 7(1):69-80.
        View in: PubMed
      125. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992 Jul; 30 Suppl A:117-22.
        View in: PubMed
      126. Chambers HF, Miick C. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar; 36(3):656-61.
        View in: PubMed PMC190574
      127. Lee BL, Padula AM, Täuber MG, Chambers HF, Sande MA. Oral SCH 39304 as primary, salvage, and maintenance therapy for cryptococcal meningitis in AIDS. J Acquir Immune Defic Syndr. 1992; 5(6):600-4.
        View in: PubMed
      128. Gerberding JL, Miick C, Liu HH, Chambers HF. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Dec; 35(12):2574-9.
        View in: PubMed PMC245433
      129. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991 Dec; 35(12):2505-8.
        View in: PubMed PMC245421
      130. Barg N, Chambers H, Kernodle D. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase. Antimicrob Agents Chemother. 1991 Oct; 35(10):1975-9.
        View in: PubMed PMC245310
      131. Chambers HF. Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 1991 Jan; 12(1):29-35.
        View in: PubMed
      132. Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep; 162(3):705-10.
        View in: PubMed
      133. Stratton CW, Gelfand MS, Gerberding JL, Chambers HF. Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus. Antimicrob Agents Chemother. 1990 Sep; 34(9):1780-2.
        View in: PubMed PMC171924
      134. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun; 34(6):1227-31.
        View in: PubMed PMC171789
      135. Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Jun; 161(6):1170-6.
        View in: PubMed
      136. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr; 34(4):510-4.
        View in: PubMed PMC171634
      137. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989 Nov 4; 2(8671):1071-3.
        View in: PubMed
      138. Kerlikowske K, Chambers HF. Kingella kingae endocarditis in a patient with the acquired immunodeficiency syndrome. West J Med. 1989 Nov; 151(5):558-60.
        View in: PubMed PMC1026808
      139. Padula A, Chambers HF. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother. 1989 Oct; 33(10):1822-3.
        View in: PubMed PMC172764
      140. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989 Sep; 33(9):1522-5.
        View in: PubMed PMC172694
      141. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob Agents Chemother. 1989 Jul; 33(7):995-9.
        View in: PubMed PMC176051
      142. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother. 1989 Jul; 33(7):991-4.
        View in: PubMed PMC176050
      143. Chambers HF, Archer G, Matsuhashi M. Low-level methicillin resistance in strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1989 Apr; 33(4):424-8.
        View in: PubMed PMC172453
      144. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med. 1988 Oct 15; 109(8):619-24.
        View in: PubMed
      145. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med. 1988 Aug; 85(2):172-6.
        View in: PubMed
      146. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul; 158(1):7-12.
        View in: PubMed
      147. Chambers HF. Methicillin-resistant staphylococci. Clin Microbiol Rev. 1988 Apr; 1(2):173-86.
        View in: PubMed PMC358041
      148. Chambers HF, Hackbarth CJ. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1987 Dec; 31(12):1982-8.
        View in: PubMed PMC175839
      149. Chambers HF. Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a. Antimicrob Agents Chemother. 1987 Dec; 31(12):1919-24.
        View in: PubMed PMC175828
      150. Sachdeva M, Hackbarth C, Stella FB, Chambers HF. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci. Antimicrob Agents Chemother. 1987 Oct; 31(10):1549-52.
        View in: PubMed PMC174987
      151. Gerberding JL, Bryant-LeBlanc CE, Nelson K, Moss AR, Osmond D, Chambers HF, Carlson JR, Drew WL, Levy JA, Sande MA. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis. 1987 Jul; 156(1):1-8.
        View in: PubMed
      152. Chambers HF, Morris DL, Täuber MG, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med. 1987 Jun; 106(6):833-6.
        View in: PubMed
      153. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis. 1987 Mar; 155(3):581-5.
        View in: PubMed
      154. Hackbarth CJ, Chambers HF, Stella F, Shibl AM, Sande MA. Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. J Antimicrob Chemother. 1986 Nov; 18 Suppl D:65-9.
        View in: PubMed
      155. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Sep; 30(3):382-4.
        View in: PubMed PMC180564
      156. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Apr; 29(4):611-3.
        View in: PubMed PMC180452
      157. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal titer as a predictor of outcome in endocarditis. Eur J Clin Microbiol. 1986 Feb; 5(1):93-7.
        View in: PubMed
      158. Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest. 1985 Jul; 76(1):325-31.
        View in: PubMed PMC423778
      159. Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May; 27(5):685-7.
        View in: PubMed PMC180132
      160. Morris DL, Chambers HF, Morris MG, Sande MA. Hemodynamic characteristics of patients with hypothermia due to occult infection and other causes. Ann Intern Med. 1985 Feb; 102(2):153-7.
        View in: PubMed
      161. Chambers HF, Mills J, Drake TA, Sande MA. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 1984 Nov-Dec; 6 Suppl 4:S870-4.
        View in: PubMed
      162. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul; 26(1):61-4.
        View in: PubMed PMC179917
      163. Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. J Infect Dis. 1984 Jun; 149(6):894-903.
        View in: PubMed
      164. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore). 1983 May; 62(3):170-7.
        View in: PubMed
      Henry's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP